Mentari Therapeutics, Inc. announced a $200 million private placement of common stock and pre-funded warrants to healthcare investors including Fairmount, Venrock, and Blackstone. This additional financing, occurring concurrently with a previously announced $290 million private placement, is intended to most likely extend Mentari's cash runway into 2029 to support clinical development of its migraine prevention pipeline. InMed Pharmaceuticals Inc. is a biotechnology company that develops therapies for migraine prevention.
